Seeking to simultaneously target lymphoma cells with CD19-specific CAR-T cells and the FDA-approved BCL2 inhibitor venetoclax (Figure 2), investigators led by Marco Ruella designed CAR-T cells with an intrinsic resistance to venetoclax-mediated apoptosis induction by overexpressing a mutated BCL2 version in CD19-specific CAR-T cells (BCL-2(F104L)-CART19) [31]. Here, BCL2 is linked to lymphoma.